Scott Ward Joins Endologix’s Board of Directors

 Endologix LLC has appointed Scott Ward to its Board of Directors.
 
Ward was most recently CEO and board chairman of Cardiovascular Systems.  Over the course of his career, he has served on more than 15 public and private company boards as well as numerous non-profit boards, including Gillette Children’s, where he is currently Philanthropy Board chairman. Ward has more than 40 years of healthcare industry experience, and nearly 30 of those he spent at Medtronic serving in various leadership roles including senior vice president and president of the CardioVascular, Neurological and Diabetes businesses. Ward is the founder of Raymond Holdings, a firm with activities in venture capital, strategy and transactional advisory services for medical technology, and life science companies. 
 
“We are delighted to announce Scott Ward as the newest member of the Endologix Board of Directors,” Endologix CEO/President Matt Thompson, M.D., said. “Scott’s extensive background in the healthcare sector, highlighted by his tenure at Medtronic and leadership at Cardiovascular Systems, brings an invaluable depth of experience to our team. Scott’s expertise in the medical device industry and his commitment to innovation will be pivotal as we forge ahead to advance our product portfolio and the DETOUR System’s full market release.”
 
“I am honored to be appointed to the Endologix Board of Directors,” Ward stated. “My four decades in the healthcare industry have shown me the transformative power of innovative medical solutions in patient care. I eagerly anticipate collaborating with the board and leadership team to advance Endologix’s strategic objectives. The Endologix therapeutic portfolio, particularly the DETOUR System with its novel approach to treating complex PAD, stands out as a testament to the company’s commitment to patients with vascular disease. I am committed to leveraging my experience to contribute to the company’s dynamic future and the continuous improvement in patient care.”
 
Endologix LLC is a global medical device company developing therapies for interventional vascular disease treatment. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases with no clinically relevant unmet needs. Endologix’s commercial products, including the AFX 2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, are designed to treat various vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas, and Santa Rosa, Calif.